Related Experiment Videos
Ticlopidine-induced interstitial pulmonary disease: a case report
C F Persoz1, F Cornella, P Kaeser
1Department of Internal Medicine, Hôpital des Cadolles, Neuchâtel, Switzerland. persoz@deckpoint.ch
Chest
|June 16, 2001
Summary
Ticlopidine, a medication for stroke prevention, can cause rare lung and colon inflammation. This case highlights severe hypoxemia from concurrent interstitial lung disease and colitis, requiring prednisone treatment.
Area of Science:
- Pulmonology
- Gastroenterology
- Pharmacology
Background:
- Ticlopidine is an antiplatelet medication used to prevent thrombotic events.
- Interstitial lung disease and colitis are potential, though rarely reported, side effects of ticlopidine.
Observation:
- A patient developed interstitial pulmonary disease concurrently with lymphocytic colitis while undergoing ticlopidine treatment for transient ischemic cerebrovascular accidents.
- The patient experienced severe hypoxemia due to the pulmonary condition.
Findings:
- Discontinuation of ticlopidine was necessary.
- A prolonged course of prednisone was required to manage both the pulmonary and intestinal symptoms.
Implications:
- This case underscores the potential for ticlopidine to induce simultaneous, severe lung and colon inflammation.
- Clinicians should maintain a high index of suspicion for ticlopidine-induced pulmonary and gastrointestinal toxicity, especially when patients present with respiratory symptoms.
- Early recognition and management are crucial for favorable outcomes in patients experiencing these adverse drug reactions.